文献速递膀胱癌与上尿路尿路上皮癌

美国膀胱癌、其他癌症与非癌症人群的医疗利用与费用

Utilization and Costs Among Bladder Cancer, Other Cancer, and Noncancer Populations in the United States.
PubMed 文献 · Urology · 2026-06-14

基于2015-2022年医疗支出面板调查的165,665人年观察,比较膀胱癌、其他癌症与非癌症人群的医疗利用和支出,并评估种族差异。膀胱癌患者急诊就诊率高于其他两组,但总支出与其他癌症相似;少数族裔膀胱癌患者的医疗利用和支出差异最明显。

要点

  • 膀胱癌患者急诊就诊率显著高于非癌症和其他癌症人群。
  • 膀胱癌患者总支出与其他癌症患者相似,但高于非癌症人群。
  • 少数族裔患者的医疗利用和支出更高,在膀胱癌人群中差异最明显。

核心结论

  • 膀胱癌患者急诊就诊利用显著高于非癌症和其他癌症患者,但总费用与其他恶性肿瘤相似。
  • 按种族/族裔分层的医疗利用和支出差异明显,且在膀胱癌患者中最突出。

研究设计与样本

  • 基于医疗支出面板调查(2015-2022)的回顾性队列分析,纳入165,665人年观察,来自85,194名个体。
  • 将受访者分为膀胱癌、非膀胱癌癌症(前列腺、结直肠、肺、黑色素瘤、淋巴瘤、乳腺、妇科)和无癌症史三组。
  • 采用调查加权回归模型比较年度医疗利用(急诊、门诊、住院、处方复合指标)和支出(总额及自付)。

主要发现

  • 在165,665人年中,膀胱癌占0.2%,其他癌症占4.5%,无癌症占95.3%,平均年龄55.7岁。
  • 与非膀胱癌癌症相比,膀胱癌患者调整后总复合医生交互无显著差异(IRR 1.10,95%CI 0.96-1.26),但非膀胱癌患者急诊就诊更少(IRR 0.65,95%CI 0.46-0.92)。
  • 与膀胱癌相比,无癌症患者调整后总支出显著更低(IRR 0.74,95%CI 0.59-0.91),自付支出无差异;膀胱癌与非膀胱癌癌症患者总支出和自付支出相似。
  • 少数族裔患者较非西班牙裔白人患者总医生交互(IRR 1.97,95%CI 1.26-3.09)、门诊就诊(IRR 2.54,95%CI 1.56-4.12)和总医疗支出(IRR 1.73,95%CI 1.01-2.97)更高。

临床怎么用

  • 应关注膀胱癌患者较高的急诊就诊负担,优化急诊与门诊衔接管理。
  • 膀胱癌费用负担与其他恶性肿瘤相当,资源分配需综合考虑。
  • 针对少数族裔膀胱癌患者应制定针对性干预以减少医疗利用和支出差异。

局限性

  • 研究为观察性设计,可能存在残余混杂。
  • 膀胱癌样本比例较小(0.2%),可能影响亚组分析效能。
  • 医疗利用和支出基于自我报告,可能存在回忆偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate healthcare utilization (HCU) and expenditures across bladder cancer (BCa), other cancers, and noncancer groups and to assess for racial and ethnic disparities. PATIENTS AND METHODS: Using the Medical Expenditure Panel Survey (2015-2022), we identified 165,665 respondent-year observations from 85,194 unique individuals and categorized respondents as BCa, non-BCa cancers (prostate, colorectal, lung, melanoma, lymphoma, breast, gynecologic), or no cancer history. Survey-weighted regression models were used to compare and estimate incidence rate ratios of annual HCU (a composite of emergency, outpatient, inpatient encounters, prescriptions) and expenditures (total and out-of-pocket). RESULTS: Among 165,665 respondent-years (mean age 55.7 years), 0.2% had BCa, 4.5% other cancers, and 95.3% no cancer. Compared to BCa, adjusted total composite physician interactions were similar in the no-cancer group (IRR 0.97, 95% CI 0.85-1.11) and the non-BCa cancers (IRR 1.10, 0.96-1.26). Non-BCa patients had fewer ED visits than BCa patients (IRR 0.65, 0.46-0.92). Compared to BCa patients, adjusted total spending was significantly lower in no-cancer patients (IRR 0.74, 0.59-0.91), whereas adjusted OOP spending did not differ. Total and OOP spending were also similar between BCa and non-BCa patients. Racial/ethnic minority patients had higher total physician interaction (IRR 1.97, 1.26-3.09), outpatient visits (IRR 2.54, 1.56-4.12) and total healthcare expenditures (IRR 1.73, 1.01-2.97) than non-Hispanic White patients. CONCLUSION: BCa patients showed significantly higher HCU in emergency visits compared to both noncancer and other cancer patients. BCa patients did not incur higher expenses than other malignancies. Disparities in HCU and expenditure stratified by race/ethnicity were evident and most pronounced among BCa patients.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Malshy K, Lim K, Jia Y, et al. Utilization and Costs Among Bladder Cancer, Other Cancer, and Noncancer Populations in the United States. Urology. 2026. PMID: 42289202. doi:10.1016/j.urology.2026.06.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。